Tscan Therapeutics, INC 8-K filings

TScan Therapeutics announced second quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 3 ALLOHA-2 study and positive initial data from its Phase 1 ALLOHA study.

TScan Therapeutics reported Q1 2026 financial results, highlighting progress in its heme and solid tumor programs with key clinical trial milestones expected in Q2 and H2 2026.

TScan Therapeutics announced its Q4 and full-year 2025 financial results, highlighting positive clinical data for its heme program and FDA clearance for new TCR-T candidates.

TScan Therapeutics presented promising clinical data for its TSC-101 therapy in hematologic malignancies and outlined strategic plans for its solid tumor and autoimmunity programs at the J.P. Morgan Healthcare Conference.

TScan Therapeutics' Board of Directors approved a retention program for key executives, including cash and equity awards tied to the advancement of the TSC-101 pivotal trial.

TScan Therapeutics reports Q3 2025 financial results, outlines strategic shift to prioritize heme malignancies, pauses solid tumor enrollment, and extends cash runway into H2 2027.

TScan Therapeutics announced a strategic prioritization of its heme program, a 30% workforce reduction, and an extension of its cash runway into H2 2027, following FDA alignment on its TSC-101 pivotal study design.

TScan Therapeutics provided an updated corporate presentation detailing revised development milestones, pipeline advancements, and promising Phase 1 data for its hematologic malignancies program.

TScan Therapeutics, Inc. announced the appointment of Leiden Dworak as its new Principal Accounting Officer, effective August 14, 2025.

TScan Therapeutics reports increased Q2 2025 revenue and R&D expenses, with cash runway into Q1 2027, and anticipates key clinical milestones for its cancer therapies.

TScan Therapeutics, Inc. announced the results of its 2025 annual meeting of stockholders, where Class I directors were elected and Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

TScan Therapeutics announced its Q1 2025 financial results, highlighting progress in its PLEXI-T and ALLOHA clinical trials and anticipating key milestones by year-end.

TScan Therapeutics reports financial results for Q4 and full year 2024, showcasing clinical advancements in its ALLOHA and PLEXI-T trials, and securing financial runway into Q1 2027.

TScan Therapeutics has entered into a securities purchase agreement to sell pre-funded warrants for approximately $30 million in gross proceeds.

TScan Therapeutics has entered into a term loan agreement with Silicon Valley Bank for up to $52.5 million, replacing its existing convertible debt facility and extending the loan maturity to 2029.

TScan Therapeutics reported promising updated data from its ALLOHA Phase 1 trial, showing a significant reduction in relapse rates for patients receiving their TCR-T therapies, and announced plans for a pivotal trial in the second half of 2025.

TScan Therapeutics converted $15 million of its loan into common stock at a price of $4.785 per share.

TScan Therapeutics announced third quarter 2024 financial results and provided a corporate update, highlighting positive data from their ALLOHA Phase 1 trial and progress in their solid tumor program.

TScan Therapeutics has entered into a second amendment to its lease, securing additional space to support its growing operations.

TScan Therapeutics announced its second quarter 2024 financial results, highlighted by an FDA RMAT designation for its lead TCR-T therapy candidates and progress in clinical trials.

TScan Therapeutics has appointed Garry Nicholson to its Board of Directors, while Timothy Barberich has resigned as Chairman, with Stephen Biggar assuming the role.

TScan Therapeutics announced its first quarter 2024 financial results, highlighted by the first patient dosed in its Phase 1 solid tumor trial and a successful $167.8 million public offering.

TScan Therapeutics has priced an upsized public offering of common stock and pre-funded warrants, expected to generate gross proceeds of approximately $150.1 million.

TScan Therapeutics announced an update on its clinical programs, highlighting progress in both solid tumor and heme malignancy treatments, with the first solid tumor patients expected to be dosed in early May 2024.

TScan Therapeutics has appointed Chrystal U. Louis as its new Chief Medical Officer, succeeding Deborah Barton who is departing for personal reasons but will remain as a consultant.

TScan Therapeutics announced positive results from its Phase 1 clinical trials for hematologic malignancies, progress in its solid tumor program, and its financial results for the fourth quarter and full year 2023.

TScan Therapeutics has appointed Jason A. Amello as its new Chief Financial Officer, effective January 29, 2024.